

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](http://FDI Lab - SciCrunch.org) on Apr 13, 2025

## Brilliant Violet 785(TM) anti-mouse CD4

RRID:AB\_2565843

Type: Antibody

---

### Proper Citation

(BioLegend Cat# 100453, RRID:AB\_2565843)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2565843](http://antibodyregistry.org/AB_2565843)

**Proper Citation:** (BioLegend Cat# 100453, RRID:AB\_2565843)

**Target Antigen:** CD4

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 785(TM) anti-mouse CD4

**Description:** This monoclonal targets CD4

**Target Organism:** mouse

**Clone ID:** Clone GK1.5

**Antibody ID:** AB\_2565843

**Vendor:** BioLegend

**Catalog Number:** 100453

**Record Creation Time:** 20231110T035157+0000

**Record Last Update:** 20240725T062033+0000

---

### Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD4.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 24 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.

Bonetti L, et al. (2024) A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation. *Cell metabolism*, 36(8), 1726.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. *Cell*, 187(3), 624.

Kenney LL, et al. (2024) mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity. *Cell reports. Medicine*, 5(9), 101717.

Joshi S, et al. (2024) Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis. *Cell reports*, 43(4), 114096.

Osorio JC, et al. (2023) The antitumor activities of anti-CD47 antibodies require Fc-Fc $\gamma$ R interactions. *Cancer cell*, 41(12), 2051.

First NJ, et al. (2023) *Bordetella* spp. block eosinophil recruitment to suppress the generation of early mucosal protection. *Cell reports*, 42(11), 113294.

Huseni MA, et al. (2023) CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. *Cell reports. Medicine*, 4(1), 100878.

Pankhurst TE, et al. (2023) MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity. *Cell reports*, 42(4), 112310.

Guo M, et al. (2023) Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control. *Cell reports*, 42(9), 113047.

Briukhovetska D, et al. (2023) T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. *Immunity*, 56(1), 143.

Soriano-Baguet L, et al. (2023) Pyruvate dehydrogenase fuels a critical citrate pool that is essential for Th17 cell effector functions. *Cell reports*, 42(3), 112153.

Blomberg OS, et al. (2023) IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. *Cancer cell*, 41(1), 106.

Gonçalves R, et al. (2023) SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. *iScience*, 26(2), 105972.

Earley ZM, et al. (2023) GATA4 controls regionalization of tissue immunity and commensal-driven immunopathology. *Immunity*, 56(1), 43.

Hailmichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.

Mastandrea I, et al. (2022) Isolation and characterization of the immune cell fraction from murine brain tumor microenvironment. *STAR protocols*, 3(1), 101106.

Cardoso A, et al. (2021) Interleukin-10 induces interferon- $\gamma$ -dependent emergency myelopoiesis. *Cell reports*, 37(4), 109887.

Magod P, et al. (2021) Exploring the longitudinal glioma microenvironment landscape uncovers reprogrammed pro-tumorigenic neutrophils in the bone marrow. *Cell reports*, 36(5), 109480.

Monteiro de Oliveira Novaes JA, et al. (2021) Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. *Cancer prevention research (Philadelphia, Pa.)*, 14(3), 313.